{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-024413","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.855883+00:00","generated_at":"2026-05-18T09:39:41.443460+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments","bullets":["Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.","Purchase price of $300M paid in full at closing on June 27, 2025.","Purchaser's annual cap equals 60% of Bayer royalties on first $500M of net sales; hard cap at 145% of purchase price.","Company granted security interest in assets related to purchased royalty payment; change of control triggers option to assume or pay adjusted amount."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-024413","json":"https://secwatch.observer/filing/0001140361-25-024413.json","markdown":"https://secwatch.observer/filing/0001140361-25-024413.md","text":"https://secwatch.observer/filing/0001140361-25-024413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/0001140361-25-024413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/ef20051467_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:39:41.443460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}